Bevacizumab for advanced cervical cancer

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)

“Benefit of adding bevacizumab to CT for cervical cancer is sustained: OS curves remain separated with ext. follow-up” and “Unfortunately though bevacizumab is out of reach of many patients living in #LMICs” (RT @oncology_bg see Tweets)